Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2006

View Archived Issues

Lasofoxifene improves bone parameters in postmenopausal women

Phase I study finds intraputaminal CERE-120 feasible in Parkinson's disease

Anticancer activity of tetrathiomolybdate assessed in preclinical studies

Motexafin-rituximab combination shows promise in B-cell lymphoma cells

New evidence that the ERK-Kv4.2 signaling pathway represents a target for pain

Novel cardenolide UNBS-1450 active in cancer models

Docetaxel nanoparticle-aptamer bioconjugate effective in prostate cancer model

Single confirmatory phase III study planned for MC-1

Phase III study begins for DN-101 in advanced prostate cancer

Organon and Radboud University to target gene involved in tumor growth

Array achieves research milestone in Genentech collaboration

Enrollment completed in Entereg phase III program

New phase I study investigates MEDI-545 for lupus

Positive phase II findings for Ardana's testosterone cream

Raloxifene effective as tamoxifen in preventing invasive breast cancer

New compounds to target specific adenosine receptor subtypes presented

Nexavar receives European orphan medicinal product status for liver cancer

Saforis NDA filed for oral mucositis

Recent patents report new treatment strategies for respiratory diseases

New therapeutic agents for psychological disorders disclosed

New antiviral and antimycobacterial agents described in recent patents

Major component of green tea may be useful in ocular diseases

Targeting the mTOR pathway -- a promising therapeutic approach in polycystic kidney disease

Spotlight on chemokine CXCR4 receptors and cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...